LH:NYE-Laboratory Corporation of America Holdings (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 227.22

Change

+0.21 (+0.09)%

Market Cap

USD 18.96B

Volume

0.51M

Analyst Target

USD 228.47
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

-0.57 (-0.21%)

USD 199.35B
IQV IQVIA Holdings Inc

+2.69 (+1.12%)

USD 43.52B
A Agilent Technologies Inc

+0.66 (+0.48%)

USD 39.94B
DGX Quest Diagnostics Incorporated

+0.10 (+0.06%)

USD 17.18B
CRL Charles River Laboratories

-0.11 (-0.05%)

USD 10.65B
QGEN Qiagen NV

+0.02 (+0.04%)

USD 10.30B
VNRX Volitionrx Ltd

-0.05 (-7.58%)

USD 0.06B
ENZ Enzo Biochem Inc

-0.01 (-0.89%)

USD 0.06B
TMO Thermo Fisher Scientific Inc

-0.37 (-0.06%)

N/A
MTD Mettler-Toledo International I..

+19.22 (+1.39%)

N/A

ETFs Containing LH

CAMX Cambiar Aggressive Value .. 4.42 % 0.00 %

+0.05 (+-1.47%)

USD 0.06B
DDOC:XETRA Global X Telemedicine & D.. 4.17 % 0.00 %

-0.09 (-1.47%)

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.17 % 0.00 %

+0.07 (+-1.47%)

USD 4.62M
EDOC:SW Global X Telemedicine & D.. 3.97 % 0.00 %

-0.10 (-1.47%)

N/A
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.17 (+-1.47%)

N/A
BVNSC 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.03% 31% F 26% F
Dividend Return 0.95% 71% C- 23% F
Total Return 0.92% 38% F 23% F
Trailing 12 Months  
Capital Gain 10.73% 46% F 46% F
Dividend Return 1.40% 71% C- 21% F
Total Return 12.13% 38% F 40% F
Trailing 5 Years  
Capital Gain 31.58% 25% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.58% 25% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 10.62% 46% F 70% C-
Dividend Return 11.02% 46% F 65% D
Total Return 0.40% 57% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 32.30% 31% F 31% F
Risk Adjusted Return 34.12% 38% F 52% F
Market Capitalization 18.96B 67% D+ 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector